caledonia
Senior Member
- Messages
- 4,617
I thought it was mid Feb, due to the FOIA info.
Someone is telling me they heard at the CFSAC it's now January?
Someone is telling me they heard at the CFSAC it's now January?
I thought it was mid Feb, due to the FOIA info.
Someone is telling me they heard at the CFSAC it's now January?
There are a number of documents coming up.
The FINAL version of the AHRQ evidence review comes out on DECEMBER 9th (should be posted on the AHRQ and P2P sites). I do not know when the document on the disposition of submitted comments is released though. (count these are documents # 1 and 2)
The draft P2P report should come out close to 24 hours after the close of the meeting (so the 11th or 12th of December).
The clock for submitted comments starts ticking right away and we have 30 days (from the release of the draft report) to submit comments about the contents of the report.
I believe the next step is that the panel goes over the public comments and does final edits and 2 weeks after that releases the final report.
So at a guess, I think the final P2P report comes out before the end of January.
As I understand the timeline, the IOM reports comes out mid-February or early March. (fwiw - based on the timeline, I am pretty sure IOM has finished all of its writing, editing and both the internal and external review of the document.)
Final evidence review has been published:
http://www.effectivehealthcare.ahrq.gov/ehc/products/586/2004/chronic-fatigue-report-141209.pdf
Did they change anything for the better?
(or is this and the P2P being discussed in another thread? couldn't find one)
Given that a score of 65 or less on the SF - 36 physical functioning scale was defined as disability for entry in
to the trial, using a score of 60 or greater on the same scale to define recovery is contradictory.
Given that a score of 65 or less on the SF - 36 physical functioning scale was defined as disability for entry in
to the trial, using a score of 60 or greater on the same scale to define recovery is contradictory.
Timing for Public Posting of the Draft P2P Report for ME/CFS![]()
From *********
To DAVID.MURRAY2 DAVID.MURRAY2@NIH.GOV
Cc francis.collins francis.collins@nih.gov
Thu, Dec 18, 2014 2:45 pm
Dear Dr. Murray,
It is my understanding that the Draft P2P Report for ME/CFS would be posted today (12/18/2014). I have tried contacting your office multiple times today to determine if the Report would be posted by close of business today (12/18/2014). I was only able to get through to your office at 3:00 pm (EST) and I was told that "they were working on getting the report posted, but no time frame on the 18th could be provided for when the report would be available for viewing on the ODP website. It is now 5:30 pm (EST) and the Draft Report has still not been posted on the ODP website nor has any information been posted on the website or by e-mail notification that there will be a delay in posting.
As a patient with this illness, I am very disappointed that your office made a public announcement that the draft report would be available today and no one in your office was able to answer 1) if the date of posting of December 18, 2014 was to be before close of business, or 2) by the end of the day at 11:59 pm (E.S.T.) on December 18, 2014, or 3) if the posting of the report would be delayed and no posting would occur on December 18, 2014.
I would appreciate a follow-up communication to this e-mail with an explanation as to the current status of the posting of the Draft P2P Report for ME/CFS.
Very truly your,
***************
(***)
*
*I request that my contact information be redacted should this e-mail communication be released to the public.
Re: Timing for Public Posting of the Draft P2P Report for ME/CFS![]()
From Murray, David (NIH/OD) [E] (NIH/OD) [E] david.murray2@nih.govhide details![]()
Thu, Dec 18, 2014 2:58 pm
To xxxxxxxx
M********,
The draft report went live on our website at about 5:30 today. You can find it
at:
https://prevention.nih.gov/docs/programs/mecfs/ODP-MECFS-DraftReport.pdf
I’m sorry you had trouble reaching our office. We had an end-of-year staff
luncheon midday, but you should have been able to reach us this morning or later
this afternoon.
David Murray
***************************************************
David M. Murray, Ph.D.
Associate Director for Prevention
Director, Office of Disease Prevention
Office of the Director
National Institutes of Health
NIH/OD/DPCPSI/ODP
tel: (301) 496-1508
fax: (301) 480-7660 6100 Executive Boulevard, 2B03
david.murray2@nih.gov<mailto:david.murray2@nih.gov> Rockville, MD
20892
Wanda Davis
Assistant to the Director (301) 496-1508
Office of Disease Prevention wanda.davis@nih.gov<mailto:wanda.davis@nih.gov>
32 ME/CFS exists.
52 ...and a research focus on men
88 Clinical studies have focused on predominantly Caucasian, middle-aged women.
92 Although psychological repercussions (e.g., depression) often follow ME/CFS, this is not a psychological disease in etiology.
99 Future studies should distinguish between ME/CFS alone, ME/CFS with comorbidities, and other 100 diseases
105 A clear case definition with validated diagnostic tools is required before studies can be conducted.
113 Existing treatment studies (cognitive behavioral therapy [CBT] and graded exercise therapy [GET]) demonstrate measurable improvement, but this has not translated to improvements in quality of life (QOL). Thus, they are not a primary treatment strategy and should be used as a component of multimodal therapy.
135 In many cases, lack of instructions or guidance for including graded exercise therapy often causes additional suffering, creating fear of harm from a comprehensive self-management program that may include some physical activity
159 Patient- centered tools that use simple statements need to be developed to ensure that the patients understand the questions.
191 The dissemination of diagnostic and therapeutic recommendations should focus on primary care providers.
198 Findings in the literature are inconsistent, and there are many gaps (e.g., Is ME/CFS one disease?).
213 Create new knowledge. Investing in bench-to-bedside to policy research for ME/CFS is recommended
244 Researchers should be encouraged to develop a repository for qualitative and quantitative work. Similar to cancer registries, there is much to learn by developing a registry/repository of all patients with ME/CFS
282 Studies addressing biopsychosocial parameters (including the mind-body connection), function, and QOL should be encouraged.
313 We believe ME/CFS is a distinct disease that requires a multidisciplinary care team (e.g., physicians, nurses, case managers, social workers, psychologists) to optimize care.
362 The modest benefit from CBT should be studied as adjunct to other modalities of treatment such as self-management..
365 We recommend that the NIH and the FDA convene a meeting on the state of ME/CFS treatment.
379 Thus, for needed progress to occur we recommend (1) that the Oxford definition be retired, (2) that the ME/CFS community agree on a single case definition (even if it is not perfect), and (3) that patients, clinicians, and researchers agree on a definition for meaningful recovery..
384 We believe there is a specific role for multimodal therapy.